Somatostatin analogs in the medical management of occult bleeding of the lower digestive tract

Julie Martin-Grace, Gianluca Tamagno, Julie Martin-Grace, Gianluca Tamagno

Abstract

The management of occult bleeding from the lower digestive tract can be very challenging. In cases of identified angiodysplasia, the first line management options can be limited by a number of clinical or anatomical factors and an alternative approach might be required, including the use of medications. Somatostatin analogs have been considered as an effective and well-tolerated alternative management option in a number of cases where the endoscopic therapeutic approach is not practical or is unsuccessful, in patients with coagulopathies or who need concomitant anticoagulation or antiplatelet treatment. Despite the lack of double-blinded randomized placebo-control trials and despite the limitations of the available evidence in the literature, including small sample size, variable dosing, and administration routes, there is a consistent agreement in the literature that somatostatin analogs are a safe, well-tolerated, and effective therapeutic option for managing refractory or occult bleeding from the lower digestive tract, with particular reference to patients with angiodysplasia, where endoscopic or surgical management is either not feasible or unsuccessful and other pharmacological options are not preferred.

References

    1. American Gastroenterological Association. American Gastroenterological Association medical position statement: evaluation and management of occult and obscure gastrointestinal bleeding. Gastroenterology. 2000;118(1):197–200. doi: 10.1016/s0016-5085(00)70429-x.
    1. Foutch P. G. Angiodysplasia of the gastrointestinal tract. The American Journal of Gastroenterology. 1993;88(6):807–818.
    1. Vargo J. J. Clinical applications of the argon plasma coagulator. Gastrointestinal Endoscopy. 2004;59(1):81–88. doi: 10.1016/s0016-5107(03)02296-x.
    1. Sami S. S., Al-Araji S. A., Ragunath K. Review article: gastrointestinal angiodysplasia—pathogenesis, diagnosis and management. Alimentary Pharmacology and Therapeutics. 2014;39(1):15–34. doi: 10.1111/apt.12527.
    1. Junquera F., Feu F., Papo M., et al. A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia. Gastroenterology. 2001;121(5):1073–1079. doi: 10.1053/gast.2001.28650.
    1. Lewis B. S., Salomon P., Rivera-MacMurray S., Kornbluth A. A., Wenger J., Waye J. D. Does hormonal therapy have any benefit for bleeding angiodysplasia? Journal of Clinical Gastroenterology. 1992;15(2):99–103. doi: 10.1097/00004836-199209000-00004.
    1. Ge Z.-Z., Chen H.-M., Gao Y.-J., et al. Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation. Gastroenterology. 2011;141(5):1629–1637. doi: 10.1053/j.gastro.2011.07.018.
    1. Garrido A., Sayago M., López J., León R., Bellido F., Márquez J. L. Thalidomide in refractory bleeding due to gastrointestinal angiodysplasias. Revista Española de Enfermedades Digestivas. 2012;104(2):69–71. doi: 10.4321/s1130-01082012000200005.
    1. Scarpignato C., Pelosini I. Somatostatin for upper gastrointestinal hemorrhage and pancreatic surgery. A review of its pharmacology and safety. Digestion. 1999;60(supplement 3):1–16.
    1. Kubba A. K., Dallai H., Haydon G. H., Hayes P. C., Palmer K. R. The effect of octreotide on gastroduodenal blood flow measured by laser Doppler flowmetry in rabbits and man. The American Journal of Gastroenterology. 1999;94(4):1077–1082. doi: 10.1016/s0002-9270(98)00810-7.
    1. Barrie R., Woltering E. A., Hajarizadeh H., Mueller C., Ure T., Fletcher W. S. Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. Journal of Surgical Research. 1993;55(4):446–453. doi: 10.1006/jsre.1993.1167.
    1. Tulassay Z. Somatostatin and the gastrointestinal tract. Scandinavian Journal of Gastroenterology. 1998;33(228):115–121. doi: 10.1080/003655298750026642.
    1. Scaglione G., Pietrini L., Russo F., Franco M. R., Sorrentini I. Long-acting octreotide as rescue therapy in chronic bleeding from gastrointestinal angiodysplasia. Alimentary Pharmacology & Therapeutics. 2007;26(6):935–942. doi: 10.1111/j.1365-2036.2007.03435.x.
    1. Burroughs A. K., Malagelada R. Potential indications for octreotide in gastroenterology: summary of workshop. Digestion. 1993;54(supplement 1):59–67. doi: 10.1159/000201079.
    1. Rossini F. P., Arrigoni A., Pennazio M. Octreotide in the treatment of bleeding due to angiodysplasia of the small intestine. American Journal of Gastroenterology. 1993;88(9):1424–1427.
    1. Nardone G., Rocco A., Balzano T., Budillon G. The efficacy of octreotide therapy in chronic bleeding due to vascular abnormalities of the gastrointestinal tract. Alimentary Pharmacology & Therapeutics. 1999;13(11):1429–1436. doi: 10.1046/j.1365-2036.1999.00647.x.
    1. Orsi P., Guatti-Zuliani C., Okolicsanyi L. Long-acting octreotide is effective in controlling rebleeding angiodysplasia of the gastrointestinal tract. Digestive and Liver Disease. 2001;33(4):330–334. doi: 10.1016/S1590-8658(01)80087-6.
    1. Tamagno G., Mioni R., de Carlo E., Maffei P., Rubello D., Sicolo N. Effects of a somatostatin analogue in occult gastrointestinal bleeding: a case report. Digestive and Liver Disease. 2004;36(12):843–846. doi: 10.1016/j.dld.2004.01.028.
    1. Junquera F., Saperas E., Videla S., et al. Long-term efficacy of octreotide in the prevention of recurrent bleeding from gastrointestinal angiodysplasia. The American Journal of Gastroenterology. 2007;102(2):254–260. doi: 10.1111/j.1572-0241.2007.01053.x.
    1. Brown C., Subramanian V., Mel Wilcox C., Peter S. Somatostatin analogues in the treatment of recurrent bleeding from gastrointestinal vascular malformations: an overview and systematic review of prospective observational studies. Digestive Diseases and Sciences. 2010;55(8):2129–2134. doi: 10.1007/s10620-010-1193-6.
    1. Bon C., Aparicio T., Vincent M., et al. Long-acting somatostatin analogues decrease blood transfusion requirements in patients with refractory gastrointestinal bleeding associated with angiodysplasia. Alimentary Pharmacology and Therapeutics. 2012;36(6):587–593. doi: 10.1111/apt.12000.
    1. Salgueiro P., Marcos-Pinto R., Liberal R., et al. Octreotide long-acting release is effective in preventing gastrointestinal bleeding due to angiodysplasias. GE Portuguese Journal of Gastroenterology. 2014;21(5):176–183. doi: 10.1016/j.jpg.2014.05.001.
    1. Nardone G., Compare D., Scarpignato C., Rocco A. Long acting release-octreotide as ‘rescue’ therapy to control angiodysplasia bleeding: a retrospective study of 98 cases. Digestive and Liver Disease. 2014;46:688–694. doi: 10.1016/j.dld.2014.04.011.
    1. Bowers M., McNulty O., Mayne E. Octreotide in the treatment of gastrointestinal bleeding caused by angiodysplasia in two patients with von Willebrand's disease. British Journal of Haematology. 2000;108(3):524–527. doi: 10.1046/j.1365-2141.2000.01897.x.
    1. Blich M., Fruchter O., Edelstein S., Edoute Y. Somatostatin therapy ameliorates chronic and refractory gastrointestinal bleeding caused by diffuse angiodysplasia in a patient on anticoagulation therapy. Scandinavian Journal of Gastroenterology. 2003;38(7):801–803. doi: 10.1080/00365520310001969.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel